Unique Gut Microbiome in HIV Patients on Antiretroviral Therapy (ART) Suggests Association with Chronic InflammationOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers examined the gut microbiome of HIV-infected patients on antiretroviral therapy (ART) compared with uninfected controls, and its relationship to chronic inflammation.
How was it studied?
The team profiled bacterial composition and alpha diversity in patients with low CD4 counts and after CD4 recovery, then correlated relative abundances of bacterial classes with circulating inflammatory and anti-inflammatory cytokines.
What did they find?
Low CD4 counts tracked with reduced alpha diversity, which normalized after CD4 recovery, yet compositional dissimilarity from controls persisted. HIV patients showed higher Negativicutes, Bacilli, and Coriobacteriia and depleted Clostridia, a pattern that correlated positively with inflammatory cytokines and negatively with anti-inflammatory cytokines.
Why it matters
The shift from obligate anaerobic Clostridia toward facultative anaerobes suggests a more aerobic, permeable gut environment sustaining Th1-skewed inflammation despite effective ART, pointing to gut dysbiosis correction as a target for improving long-term HIV outcomes.